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Abstract
 .We describe the synthesis of biodegradable poly ethyleneglycol -coupled galactolipids in which the galactose moiety is
 .separated from a diacylglyceride lipid anchor by poly ethylene glycol chains of 10, 20 or 40 oxyethylene residues
 .  .PEG . These Gal-PEG lipids Gal-PEG-Lip were incorporated in the bilayer of liposomes. The surface exposure of10r20r40
the galactose was investigated by aggregation experiments with ricinus communis agglutinin 120. Only the liposomes
containing the PEG galactolipid aggregated with the lectin. Therefore liposomes were prepared containing Gal-PEG -Lip10 10
w3 xand a trace amount of H cholesteryl oleyl ether with an average diameter of approximately 100 nm and injected
intravenously into rats. The Gal-PEG -Lip liposomes were cleared from plasma with a T1r2 of 0.3 h. Identically sized and10
composed control liposomes without the Gal-PEG -Lip had a T1r2 of approximately 12 h. The rapid plasma elimination10
of the Gal-PEG -Lip liposomes could be attributed entirely to increased uptake by the liver amounting to more than 90% of10
injected dose. Uptake by the spleen was decreased to less than 1% of injected dose. A single injection of N-acetylgalacto-
samine 1 min prior to Gal-PEG-Lip liposome administration reduced the initial rate of plasma clearance to control levels.
The increased liver uptake was almost entirely attributable to increased uptake by the Kupffer cells. Incorporation of
PEG-DSPE in the Gal-PEG -Lip liposomes only partially reversed the effect of the galactolipid with respect to liver and10
spleen uptake as well as intrahepatic distribution. These experiments demonstrate that liposome surface-exposed galactose
 .residues, even if attached at the distal end of a poly ethyleneglycol chain anchored in the liposomal bilayer are effectively
recognized by the galactose particle receptor on the Kupffer cells but fail to achieve significant targeting to the
asialoglycoprotein receptor on the hepatocytes.
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1. Introduction
Systemically administered liposomes are predomi-
nantly cleared from circulation by liver and spleen
w x1 . Macrophages, abundantly present in these organs,
are mainly responsible for this efficient clearance,
although, in the liver, hepatocytes are also able to
w xparticipate in hepatic uptake 2,3 .
Interaction with and uptake of liposomes by liver
and spleen macrophages can be substantially reduced,
 .exploiting the properties of poly ethylene glycol
w xchains on the liposome surface 4,5 . Such PEG
chains are believed to prevent or diminish the adsorp-
w xtion of opsonizing proteins 6,7 , which direct the
w xliposomes to macrophages as well as hepatocytes 8 .
As a result liposome uptake by these cells is reduced.
We measured the thickness of the fixed aqueous layer
w xaround such PEG-modified liposomes 9 and demon-
strated a good correlation between liposome circula-
tion time and the thickness of the fixed water layer
w x10 .
Attempts to actively target liposomes to hepato-
cytes, by exploiting the well-known galactose recep-
w xtor on these cells 11 , have produced variable results.
Several investigators reported increased liver uptake
of liposomes provided with surface-exposed galac-
w xtose moieties 12–20 . Only in a few instances exper-
imental evidence was offered supporting the conclu-
sion that hepatocytes are involved in this uptake
w x12,14,18 ; others reported only an increase in Kupf-
w xfer cell uptake 16,19 which was ascribed to the
w xgalactose particle receptor on these cells 21 .
The way in which the galactose moieties are ex-
posed on the liposome surface may be a determinant
in the relative affinities of such liposomes towards
the two galactose receptors. Therefore we set out to
construct galactose-exposing liposomes in which the
sugar is well-separated from the lipid-water interface
by a PEG chain of variable length. In this way we
anticipated to simultaneously exploit the anti-opsonic
action of the PEG chain and the spacer effect, im-
proving the exposure of the galactose moiety and
possibly providing an optimal configuration for inter-
action with the hepatocyte galactose receptor. Thus
far only one report appeared in literature describing
the simultaneous use of PEG as a macrophage-avoid-
ing agent and a galactosyl ligand, i.c. lactosylce-
w xramide 8 . In this case, where PEG and galactose
were on different chemical entities, the ligand caused
a shift in intrahepatic distribution in favor of the
Kupffer cells but not of the hepatocytes.
For the construction of a molecule containing both
the ligand sugar and the PEG, galactose-terminated
PEG chains of 10, 20 and 40 oxyethylene residues
were synthesized and coupled to a long-chain diacyl
glyceride for proper anchoring in the liposomal bi-
layer. The degree of exposure of the galactose residue,
anchored in the liposomal bilayer was assayed by
lectin-induced agglutination. The PEG chain length
resulting in the best galactose exposure was selected
for in vivo experiments in which we determined
plasma half-lives, liver and spleen uptake as well as
intrahepatic distribution.
2. Materials and methods
2.1. Materials
2,3,4,6-Tetra-O-benzyl-D-galactose and cholesterol
were purchased from Sigma Chemical Co. St. Louis,
.  .MO, USA . Dipalmitoylphosphatidylcholine DPPC ,
 .dipalmitoylphosphatidylglycerol DPPG , egg phos-
 .  .phatidylcholine ePC and poly ethylene glycol -di-
 .myristoylglycerol PEG-DMG with an average
 .molecular weight of 2000 40 oxyethylene residues
and the starting materials for the synthesis of the
xgalac to lip ids, the carboxyprop iony l po ly
 .oxyethylene -isopropylideneglycerols, were kindly
 .donated by NOF Corporation Tokyo, Japan .
 .Poly ethylene glycol -distearoylphosphatidyl-
 .ethanolamine PEG-DSPE , with an average PEG
molecular weight of 2000 was purchased from Avanti
 . w3 xPolar Lipids Alabaster, AL, USA . H Cholesteryl
oleyl ether was obtained from Amersham
 .Buckinghamshire, UK . Ricinus communis agglu-
 .tinin RCA 120 was obtained from Seikagaku Ko-
 .gyo Co., Ltd. Tokyo, Japan . Pronase, collagenase A
 .and DNase grade II were obtained from Boehringer
 . Mannheim, Mannheim, Germany . Nycodenz ana-
. lytical grade was purchased from Nycomed Oslo,
.Norway . All other chemicals were commercial prod-
ucts of reagent grade.
2.2. Instrumentation
1H and 13C NMR spectra were measured with a
 .JEOL JNM-GSX 270 270 MHz or JEOL JNM-
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 .GSX500 500 MHz spectrometer in CDCl using3
 .tetramethylsilane TMS as an internal standard, in
which the following abbreviations were used: ss
singlet, dsdoublet, ddsdouble doublet, ts triplet,
m s multiplet, br s broad, brs s broad singlet.
 .Chemical shifts d are given in ppm relative to TMS
 .ds0 . Column chromatography was performed on
 .  .silica gel 60 70–230 mesh Merk and gel filtration
 .on Sephadex LH-20 Pharmacia columns. Thin-layer
 .chromatography TLC was done on Silica gel 60F254
 .plates Merk . The spots were visualized by spraying
the plates with a 10% solution of phosphomolybdic
acid in ethanol followed by heating on a hot plate.
2.3. Synthesis of Gal-PEG lipids
We synthesized three galactolipids with a poly eth-
.yleneglycol chain of various chain lengths separating
the galactosyl and the diacylglyceride lipid moieties.
The synthetic procedures are summarized in Fig.
1. The three Gal-PEG lipids are the compounds
7a,b,c, with PEG chains carrying 10, 20 or 40
oxyethylene residues, respectively, and with either a
 .dipalmitoyldiglyceride a or a distearoyldiglyceride
 .b,c anchor. The synthetic procedure is described in
detail for compound 7b as an example of Gal-PEG-
lipid synthesis.
{ [ ]2.4. 1-O- a- 3-Benzyloxycarbonylpropionyl poly-
( ) } ( )oxyethylene -v-yl -2,3-O-isopropylideneglycerol 2
 w xA solution of 1-O- a- 3-carboxypropionyl poly-
 . 4  .oxyethylene -v-yl -2,3-O-isopropylideneglycerol 1
 .5.6 g, 5.1 mmol in 10 ml N,N-dimethylformamide
 .DMF was added to a stirred suspension of potas-
 .sium bicarbonate 1.0 g, 10 mmol in 10 ml DMF. To
this suspension a solution of benzyl bromide 1.3 g,
.7.7 mmol in 10 ml DMF was added and the mixture
was stirred at room temperature for 24 h. Then the
solution was poured onto cold water, and the organic
layer was extracted with chloroform, washed with
water and dried over anhydrous magnesium sulfate.
The solvent was removed in vacuo and the residue
was purified on a Sephadex LH 20 column, which
was eluted with methanol. Compound 2 was obtained
 .as a colorless oil 4.8 g, 79% .
1  . H-NMR CDCl d: 1.36, 1.42 each 3H, s, iso-3
.  .propylidene CH , 2.69 4H, s, COCH CH CO , 3.503 2 2
 . 1H, dd, Js6.0, 10.5 Hz, glycerol-H , 3.60 1H, dd,
. Js6.0, 10.5 Hz, glycerol-H , 3.61–3.69 m, oxyeth-
.  .ylene-H , 3.67 2H, m, OCH CH OCOCH CH CO ,2 2 22
 . 3.73 1H, dd, Js6.0, 9.0 Hz, glycerol-H , 4.05 1H,
. dd, J s 6.0–6.9 Hz, glycerol-H , 4.23 2H, m,
. OCH CH OCOCH CH CO , 4.28 1H, m, OCH2 2 2 22
.  . CHCH O , 5.17 2H, brs, CH -Ph , 7.36 5H, m,2 2
.CH -Ph .213  . C-NMR CDCl d: 24.8, 26.2 q, isopropyli-3
.  .dene CH =2 , 28.4, 28.5 t, COCH CH CO , 63.2,3 2 2
 . 65.8, 66.1, 68.4, 70.3, 71.7 t, CH O , 69.9 t,2
.  .oxyethylene-CH =n , 74.1 d, CH CHCH , 108.72 2 2
  . . s, isopropylidene CH C , 127.6, 127.7, 127.9 d,3 2
.  . aromatic CH , 135.2 s, aromatic C , 171.4, 171.6 s,
.COCH CH CO .2 2
{ [ ]2.5. 1-O- a- 3-Benzyloxycarbonylpropionyl poly-
( ) } ( )oxyethylene -v-yl glycerol 3
 .Compound 2 3.36 g, 2.8 mmol was treated with
 .40 ml 60% acetic acid aqueous solution vrv at
room temperature for 2 h. After removal of the
solvent, the crude mixture was purified on a silica gel
 .column, eluted with CHCl rMeOH 20:1 vrv .3
Compound 3 was obtained as a colorless oil 2.75 g,
.86% .
1  .  .H-NMR CDCl d: 2.73 4H, s, COCH CH CO ,3 2 2
 .3.45–4.35 m, oxyethylene-H and glycerol-H , 5.13
 .  .2H, brs, CH -Ph , 7.36 5H, m, CH -Ph .2213  . C-N M R CD Cl d : 29.0, 29.1 t,3
. COCH CH CO , 63.86, 63.89, 66.50, 69.0, 70.8 t,2 2
.  .CH O , 72.9 d, CH CHCH , 128.1, 128.2, 128.62 2 2
 .  .d, aromatic CH , 135.8 s, aromatic C , 172.0, 172.2
 .s, COCH CH CO .2 2
{ [ ]2.6. 1-O- a- 3-Benzyloxycarbonylpropionyl poly-
( ) } ( )oxyethylene -v-yl -2,3-O-distearoylglycerol 4
To a stirred solution of compound 3 1.7 g, 1.5
.  .mmol , triethylamine 0.4 g, 3.9 mmol and 4-di-
 .methylaminopyridine 0.09 g, 0.7 mmol in 50 ml
CHCl , a solution of stearic anhydride 1.8 g, 3.33
.mmol in 50 ml CHCl was added dropwise and the3
mixture was heated at 50–608C under nitrogen for 2
h. The reaction mixture was diluted with CHCl and3
washed with 1 N HCl, saturated aqueous NaHCO3
and brine. The organic layer was dried over anhy-
drous magnesium sulfate. The solvent was evaporated
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Fig. 1. Synthesis of spacer-armed Gal-PEG lipid.
to dryness and the residue was purified using a
column of Sephadex LH 20, which was eluted with
methanol. Compound 4 was obtained as a white solid
 .1.3 g, 51% .
1  . H-NMR CDCl d: 0.88 6H, t, Js6.3 Hz,3
 . . C H C H , 1 . 2 5 5 6 H , b r s ,2 1 63
 . . CH CH CH CH , 1.56 – 1.66 4H, m,3 14 2 22
 . . CH CH CH CH , 2.30 2H, t, Js6.5 Hz,3 2 14 22
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 . . CH CH CH CH , 2.31 2H, t, Js6.5 Hz,3 2 14 2 2
 . .  .CH CH CH CH , 2.69 4H, s, COCH CH CO ,3 2 14 2 2 2 2
 .3.60–3.69 m, oxyethylene-H and glycerol-H , 4.15
 .1H, dd, Js11.9, 6.4 Hz, glycerol-H , 4.22–4.24
  . .2H, m, CH CH O CH CH OCOCH CH CO ,2 2 19 2 2 22
 .4.32 1H, dd, Js11.9, 3.7 Hz, glycerol-H , 5.14
 .  .2H, s, CH Ph , 5.20–5.22 1H, m, OCH CHCH O ,2 22
 .7.35–7.37 5H, m, CH Ph .2
{ [ ] ( )2.7. 1-O- a- 3-Carboxypropionyl poly oxyethylene -
} ( )v-yl -2,3-O-distearoylglycerol 5
 .Compound 4 1.4 g, 0.8 mmol in 10 ml MeOH
 .was hydrogenolyzed with Pd-C 1.0 g under H at2
room temperature overnight. The catalyst was re-
moved by filtration and the filtrate was evaporated to
dryness. Compound 5 was obtained as a white solid
 .1.0 g, 78% .
1  . H-NMR CDCl d: 0.88 6H, t, Js6.4 Hz,3
 . .   . .CH CH , 1.27 56H, brs, CH CH CH CH ,2 16 3 14 2 23 2
  . . 1.58–1.62 4H, m, CH CH CH CH , 2.30 2H,3 2 14 22
 . . t, Js6.5 Hz, CH CH CH CH , 2.31 2H, t,3 2 14 2 2
  . . Js6.5 Hz, CH CH CH CH , 2.65 4H, m,3 2 14 2 2
. COCH CH CO , 3.60–3.73 m, oxyethylene-H and2 2
. glycerol-H , 4.15 1H, dd, Js11.9, 6.4 Hz, glycerol-
.   .H , 4.26–4.27 2H, m, CH CH O CH CH OC-2 2 19 2 2
. OCH CH CO , 4.33 1H, dd, Js11.9, 3.7 Hz, glyc-2 2
.  .erol-H , 5.18–5.25 1H, m, OCH CHCH O .2 213  .   . .C-NMR CDCl d: 14.1 t, CH CH , 23.03 3 2 16
  . .t , C H C H C H , 2 4 .9 , 2 5 . 03 2 2 1 5
  . . C H C H C H C H C O , 29.0 – 29.7 t,3 2 14 2 2
 .CH CH CH CH CH CH CO and succinyl-C=3 2 2 2 12 2 2
.   . . 2 , 31.9 t, CH CH CH CH , 34.2, 34.3 t,3 2 2 2 14
 . .  .CH CH CH CH CO , 62.7 t, glycerol-CH ,3 2 14 2 2 2
 . 69.0 t, glycerol-CH , 70.0 d, glycerol-CH, 70.4–2
 .70.7 t, oxyethylene-CH =n 172.0, 173.1, 173.5,2
  . .173.8 s, COCH CH CO and CH CH CO=2 .2 2 3 2 16
( { [2.8. 1-O- a- 3- 2,3,4,6-Tetra-O-benzyl-ß-D-galactos-
] } ( ) )1-O-yl carbonylpropionyl poly oxyethylene -v-yl -
( )2,3-O-distearoylglycerol 6
B e n z o t r ia z o l - 1 - y lo x y - t r i s d im e th y l -
.  .amino phosphonium hexafluorophosphate BOP
 .0.15 g, 0.34 mmol was added to a stirred solution
 .of compound 5 0.3 g, 0.19 mmol , 2,3,4,6-tetra-O-
 .benzyl-ß-D-galactose 0.12 g, 0.22 mmol and trieth-
 .  .ylamine 0.05 g, 0.5 mmol in CHCl 10 ml and3
stirred overnight at 08C. The reaction mixture was
washed once with 0.2 N HCl and brine. The organic
layer was dried over magnesium sulfate. After evapo-
ration of the solvent, the residue was purified on a
Sephadex LH 20 column, which was eluted with
 .CHCl :MeOH 1:1 vrv . Compound 6 was obtained3
 .as a white solid 0.3 g, 74% .
1  . H-NMR CDCl d: 0.88 6H, t, Js6.4 Hz,3
 . . C H C H , 1 . 2 6 5 6 H , b r s ,2 1 63
 . . CH CH CH CH , 1.56 – 1.66 4H, m,3 14 2 22
 . . CH CH CH CH , 2.30 2H, t, Js6.5 Hz,3 2 14 22
 . . CH CH CH CH , 2.31 2H, t, Js6.5 Hz,3 2 14 2 2
 . . C H C H C H C H , 2 .6 5 4 H , b rs ,3 2 1 4 2 2
.  .COCH CH CO , 3.56–3.69 m, oxyethylene-H ,2 2
 . 3.96–4.06 2H, m, H-2 and H-6a , 4.15 1H, dd,
. Js11.5, 6.5 Hz, glycerol-H , 4.20–4.22 1H, m,2
 . . CH CH O CH CH OCOCH CH CO , 4.34 1H,2 2 19 2 2 22
. dd, Js12.0, 4.0 Hz, glycerol-H , 4.39 1H, d,2
. Js10.4 Hz, OCH -Ph , 4.42 1H, d, Js10.4 Hz,2
.  .OCH -Ph , 4.61 1H, d, Js11.5 Hz, OCH -Ph , 4.712 2
 . 2H, s, OCH -Ph , 4.75 1H, d, Js11.5 Hz, OCH -2 2
.  . Ph , 4.81 1H, d, Js11.0 Hz, OCH -Ph , 4.93 1H,2
. d, J s 11.5 Hz, OCH -Ph , 5.21–5.31 1H, m,2
.  .CH CHCH , 5.58 1H, d, Js7.5 Hz, H-1 , 7.30–2 2
 .7.33 20H, m, OCH -Ph .213  .   . .C-NMR CDCl d: 14.1 q, CH CH CO ,3 3 2 16
  . . 22.7 t, CH CH CH , 24.9, 25.0 t,3 2 2 14
 . . C H C H C H C H C O , 28 .9 – 29 .7 t,3 2 14 2 2
 . . CH CH CH CH CH CH CO , 31.9 t, CH CH3 2 2 2 12 2 2 3 2
 . . C H C H C H C H C O , 34.1, 34.2 t,2 2 12 2 2
 . .CH CH CH CH CH CH CO 62.7, 63.9, 67.9,3 2 2 2 12 2 2
69.0, 69.6, 70.0, 72.9, 73.1, 73.5, 74.1, 74.7, 75.3, t,
.  .  .CH O , 70.9, t, oxyethylene-CH , 94.6 d, C-1 ,2 2
127.6, 127.7, 127.8, 127.9, 128.0, 128.2, 128.3, 128.4
 . d, aromatic CH , 137.7, 138.2, 138.3, 138.5 s,
. aromatic C , 170.8, 171.9, 173.1, 173.4 s,
 . .COCH CH CO and CH CH CO=2 .2 2 3 2 16
( { [ ]2.9. 1-O- a- 3- ß-D-Galactos-1-O-yl carbonylpro-
} ( )pionyl poly oxyethylene -v-yl-2,3-O-distearoylglyc-
( )erol 7
 .Compound 6 0.27 g, 0.13 mmol in 10 ml
 .EtOHrAcOH 9:1, vrv was hydrogenolyzed with
0.27 g Pd-C under H overnight at room temperature.2
The catalyst was removed by filtration and the filtrate
was evaporated to dryness. The residue was purified
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on a Sephadex LH20 column, which was eluted with
methanol. Compound 7 was obtained as a white solid
 .0.13 g, 60% .
1  . H-NMR CDCl d: 0.88 6H, t, Js6.4 Hz,3
 . . C H C H , 1 . 2 6 5 6 H , b r s ,2 1 63
 . . CH CH CH CH , 1.56 – 1.66 4H, m,3 14 2 22
 . . CH CH CH CH , 2.28 – 2.33 4H, m,3 2 14 22
 . .  .CH CH CH CH , 2.65 4H, s, COCH CH CO ,3 2 14 2 2 2 2
 . 3.58–3.75 m, oxyethylene-H , 3.78–3.79 1H, m,
. H-2 , 4.15 1H, dd, J s 11.5, 6.5 Hz,
 . . CH OCO CH CH , 4.23 – 4.26 2H, m,2 16 32
 . . CH CH O CH CH OCOCH CH CO , 4.34 1H,2 2 19 2 2 22
 . .dd, Js12.0, 4.0 Hz, CH OCO CH CH , 5.20–2 16 32
 . 5.22 1H, m, CH CHCH , 5.53 1H, d, Js7.5 Hz,2 2
.H-1 .
2.10. Liposome preparation
Liposomes used in the lectin-induced agglutination
experiments were prepared as follows. Solutions of
 .ePC in chloroform , Gal-PEG-Lip and, when appro-
 priate, PEG-DMG in chloroformrmethanol 2:1
.vrv were mixed in appropriate proportions in a
round-bottomed flask, and the solvent was evaporated
to dryness. When applicable, 5 mol% PEG-DMG
were added to the lipid films. After vacuum desicca-
tion for at least 1 h, 10 ml of a 10 mM Tris-HCl
 .buffer pH 7.4 containing 150 mM NaCl was added
to the flask and the lipid was suspended by shaking
for approximately 1 h at room temperature. The lipid
suspension was sonicated for 10 min after nitrogen
gas bubbling and extruded once through two stacked
polycarbonate membrane filters Costar, Cambridge
.MA, USA with 0.2-mm pore size followed by two
extrusions through 0.1-mm pore size filters using a
high pressure extruder Lipex Biomembranes, Van-
.couver, Canada . Before the lectin-induced agglutina-
tion experiments were done, such extruded liposomes
were diluted appropriately with 10 mM Tris-HCl
 .buffer pH 7.4 containing 150 mM NaCl.
Liposomes for the in vivo experiments were pre-
pared as follows: lipids from stock solutions of DPPC,
cholesterol, DPPG, Gal-PEG-Lip and PEG-DSPE in
 .chloroformrmethanol 9:1 vrv were mixed in ap-
propriate proportions with a tracer amount of
w3 xH cholesteryl oleyl ether and dried under nitrogen
gas. The dried lipid film was dissolved in cyclohex-
ane and the lipid solution was lyophilized overnight.
The lipids were hydrated at 608C in HN buffer 10
mM N-2-hydroxyethylpiperazine-NX-2-ethanesulfonic
 . .acid Hepes , 135 mM NaCl, pH 7.4 under mechani-
cal agitation for approximately 1 h. The liposomes
thus formed were extruded, as described above, 13
times through 50-nm pore size polycarbonate mem-
brane filters at 608C.
Phospholipid phosphorus was measured by phos-
w xphate assay after perchloric acid destruction 22 .
The size of the liposomes was determined by
dynamic laser light scattering using a Nicomp model
370 submicron particle analyzer Nicomp particle
.sizing systems, Santa Barbara, CA, USA . The mean
diameter of the liposomes, obtained from the volume
distribution curves produced by the particle analyzer,
varied between 75 and 105 nm.
2.11. Lectin-induced agglutination experiments
Lectin-induced agglutination experiments were
performed by a modification of the method employed
w xby Yoshioka et al. 23 .
Briefly, 2-ml aliquots of the liposome suspension
containing galactolipids was put in two cells fixed in
a spectrometer. To one of the cells 1 ml 10 mM
Tris-HCl buffer containing 150 mM NaCl and vari-
ous concentrations of RCA 120 was added, and to the
other 1 ml of 10 mM Tris-HCl buffer with 150 mM
NaCl. The agglutination at 258C was followed by
monitoring the turbidity increase at 450 nm.
2.12. Blood clearance and tissue distribution of lipo-
somes
Male Wag-Rij rats weighing 140–230 g were used
in the animal experiments. A dose of 5 mmol total
.lipid of radiolabeled liposomes per 200 g body
weight was injected via the penile vein under ether
anaesthesia. At the indicated times, blood samples
were taken from the tail vein. The samples were
centrifuged for 10 min. The amount of liposomes in
the serum was determined by measuring radioactivity
in a liquid scintillation counter. The total amount of
radioactivity in the serum was calculated by applying
 . the equation: serum volume ml s 0.0219=body
 .. w xweight g q2.66 28 . 20 h after intravenous injec-
tion of liposomes, rats were anaesthesized with nem-
butal, the spleen was removed and homogenized and
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the liver was perfused as described in the following
section. Total uptake of liposomes by liver and spleen
was determined by measuring radioactivity in the
total liver cell suspension obtained during liver cell
isolation or in the spleen homogenate, respectively.
2.13. Isolation of li˝er non-parenchymal and
parenchymal cells
Liver non-parenchymal and parenchymal cell sus-
pensions were obtained by liver perfusion with
pronase or collagenase, respectively, according to the
w xmethods described by Roerdink et al. 2 . The num-
bers of cells per suspension were determined micro-
scopically and radioactivity of each suspension was
determined. From these results the total amounts of
radioactivity per cell population, after correction for
% recovery, were calculated as described by Roerdink
w xet al. 2 .
3. Results
3.1. Lectin-induced agglutination of liposomes con-
taining Gal-PEG lipids
The three Gal-PEG-Lip species were incorporated
in phosphatidylcholine liposomes in a molar fraction
of 20%. Agglutination experiments with ricinus com-
munis agglutinin, a divalent lectin with high speci-
ficity and affinity for ß-D-galactose residues, showed
that the galactose moieties in these liposomes were
not equally accessible to the lectin. Only the prepara-
tions with the Gal-PEG -Lip were found to aggre-10
gate by addition of RCA; preparations with either one
of the other two compounds showed no evidence of
aggregation at all, as is shown in Fig. 2A. Neither the
rate nor the extent of aggregation varied significantly
upon lowering the molar fraction of the Gal-PEG-Lip
 .to 10 or even 5% Fig. 2B .
However, additional incorporation in the bilayer of
PEG-DMG, a compound used to confer plasma
w xlongevity on liposomes 10 , significantly reduced
both the rate and extent of RCA-mediated liposome
aggregation, but did not abolish it, as is shown in Fig.
3.
In spite of its relatively short lipid chain, the
PEG-DMG remains for the larger part associated
with the liposomes during prolonged incubation re-
Fig. 2. A: RCA-induced agglutination of Gal-PEG-Lip modified
 .liposomes. Liposomes 1.0 mM lipid, 2 ml composed of ePC
 .and Gal-PEG-Lip with different chain lengths 8:2 molar ratio
were mixed at 258C with 10 mM Tris-HClr150 mM NaCl pH
.7.4 , containing 0.5 mgrml RCA-120, and agglutination was
monitored spectrophotometrically at a wavelength of 450 nm.
 .  .  .Trace 1 Gal-PEG -Lip. Trace 2 Gal-PEG -Lip. Trace 310 20
Gal-PEG -Lip. B: Effect of liposomal Gal-PEG-Lip content on40
 .RCA-induced agglutination. Liposomes 0.5 mM lipid, 2 ml
composed of ePCrGal-PEG -Lip in different molar ratios were10
 .mixed at 258C with 10 mM Tris-HClr150 mM NaCl pH 7.4 ,
containing 0.25 mgrml RCA-120, and agglutination was moni-
tored as an increase in absorption at a wavelength of 450 nm.
 .  .Trace 1 PCrGal-PEG -Lips9:1. Trace 2 PCrGal-PEG -10 10
 .Lips9.5:0.5. Trace 3 PCrGal-PEG -Lips0:10.10
.sults not shown . Apparently, a sufficiently large
fraction remains liposome-associated to cause the
effect on aggregation.
3.2. Blood clearance
Since for in vivo purposes it was necessary to
prepare liposomes with a high stability in plasma, the
liposomes used for the animal experiments were
 .composed of dipalmitoylphosphatidylcholine DPPC ,
 .dipalmitoylphosphatidylglycerol DPPG and choles-
terol in a 10:1:10 molar ratio rather than of phos-
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Fig. 3. RCA-induced agglutination of liposomes doubly modified
with Gal-PEG -Lip and PEG-DMG. Liposomes 0.8 mM phos-10
. pholipid, 2 ml composed of ePCrGal-PEG -Lip 8:2 molar10
.ratio with or without 5 mol% PEG-DMG were mixed with 10
mM Tris-HClr150 mM NaCl, containing 0.5 mgrml RCA-120
and agglutination was monitored as an increase in light absorp-
 .  .tion at 450 nm. Trace 1 without PEG-DMG; Trace 2 with
PEG-DMG.
phatidylcholine alone. Assuming that this difference
in liposome composition is unlikely to significantly
influence the accessibility of the galactose residue at
 .the distal end of the PEG chain see Section 4 , we
selected the Gal-PEG -Lip for incorporation in the10
DPPCrDPPGrChol liposomes, based on the results
of the agglutination experiments described in Fig. 2.
Fig. 4 presents the plasma elimination data we ob-
tained for such liposomes. Clearly, the incorporation
of the Gal-PEG -Lip in the liposomal bilayer caused10
a dramatic drop in blood circulation time. Indepen-
dent of the Gal-PEG-Lipid concentration either 10 or
.20 mol% , the liposomes containing this lipid circu-
late with a T1r2 of less than 20 min. Control lipo-
somes of the same composition but lacking the galac-
tolipid circulate with a T1r2 of approximately 12 h,
almost 40 times longer.
Circulation time is clearly prolonged when, in
addition to the galactolipid, PEG -DSPE is incorpo-40
rated in the liposomal bilayer. The T1r2 of lipo-
somes containing 10% Gal-PEG -Lip and 2 mol%10
PEG -DSPE was increased 3-fold to a value of about40
1 h.
A single injection of 100 mg of N-acetylgalacto-
samine, a well-known inhibitor of the asialoglycopro-
tein receptor of the hepatocytes as well as of the
galactose particle receptor on the Kupffer cells
w x19,21 , resulted in a marked prolongation of the
blood circulation time of the Gal-PEG-Lip liposomes,
T1r2 being restored to the 12-h value observed for
control liposomes. This GalNAc-induced increase in
circulation time lasted for at least 2 h. This substanti-
ates our assumption that the Kupffer cell-mediated
clearance of these liposomes is mediated by the
galactose particle receptor on these cells.
3.3. Organ distribution
The differences in plasma half-lives of the lipo-
somes are reflected in the values for liposome uptake
by liver and spleen, as presented in Fig. 5. We
analyzed these organs for the amount of liposomal
radiolabel they had accumulated in a period of 20 h, a
time point when even for the most slowly clearing
liposomes the major fraction of the injected dose had
been eliminated from the blood.
Fig. 4. Plasma elimination of Gal-PEG-Lip liposomes. Lipo-
somes composed of DPPCrDPPGrCH with different amounts of
Gal-PEG -Lip and additional PEG -DSPE and labeled with10 40
w3 xH cholesteryl oleyl ether were injected intravenously into rats
at a dose of 25 mmol total lipid per kg. At the times indicated,
plasma radioactivity was assayed. Elimination of Gal-PEG -Lip10
liposomes was also monitored after injection of 100 mg N-acetyl-
 .galactosamine GalNAc 1 min prior to liposome injection. Re-
sults are presented semi-logarithmically as percent of injected
dose versus time. Data points are the means of two independent
experiments, vertical bars indicating the two separate values.
When no bar is given, the two values are within the size of the
 .  .symbol. l control liposomes without Gal-PEG -Lip B lipo-10
 .somes with 10% Gal-PEG -Lip ’ liposomes with 20% Gal-10
 .PEG -Lip v liposomes with 10% Gal-PEG -Lip plus 2%10 10
 .PEG -DSPE q liposomes with 10% Gal-PEG -Lip, after40 10
injection of GalNAc.
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Fig. 5. Organ distribution of Gal-PEG-Lip liposomes. The distri-
bution in liver, spleen and blood of the radiolabeled liposomes
described in Fig. 4 was determined 20 h after injection. The total
amounts of radioactivity associated with each of these organs is
given as percentage of injected dose. The mean of three indepen-
dent experiments is given with the bars indicating standard
deviation. Liposome compositions: control liposomes without
 .  .galactolipid control , liposomes with 10 mol% 10% Gal or 20
 .mol% 20% Gal galactolipid and with 10 mol% galactolipid plus
 .2 mol% PEG-DSPE 10% Gal-P . Open bars, blood; hatched
bars, liver; solid bars, spleen.
For the control liposomes, still 35% of the injected
dose is recovered from the blood at that time, about
19% is in the liver and almost 6% in the spleen. As is
usually found for slowly clearing liposomes, as much
as 40% of the injected dose is not accounted for by
the sum of liver, spleen and blood and presumably
represents mostly liposomes that have been able to
escape irreversibly from the blood compartment and
have become diffusely distributed in the body either
in or adsorbed to the vascular endothelial cells or
w xoutside the vascular compartment 24–26 .
Of the liposomes carrying the Gal-PEG -Lip, ei-10
ther at a 10% or a 20% concentration, less than 1%
was recovered in the blood compartment after 20 h.
An overwhelming majority of the eliminated lipo-
somes had accumulated in the liver, whereas the
spleen accounted for only 1% of the injected dose or
even less.
Liposomes containing, in addition to the galac-
tolipid, PEG -DSPE took an intermediate position,40
like in the plasma elimination studies. Twenty h after
injection, 70% of the injected dose was recovered in
the liver and 1.4% in the spleen. It is clear that with
the PEG -DSPE liposomes the effect of the Gal-40
PEG -Lip is still observed, although in this case the10
extreme bias for the liver has lessened slightly in
favor of the spleen.
3.4. Intrahepatic distribution
For obvious reasons, we prepared liposomes of a
w xsize allowing access to the hepatocytes 27 . Fig. 6
presents the results of experiments in which we iso-
lated the parenchymal and non-parenchymal cells of
rat livers after the animals had been injected with
radiolabeled liposomes and determined the radioac-
tivitiy in the isolated cell fractions. The data are
presented as % of total hepatic uptake, the sum
always amounting to 100%. The data have not been
corrected for mutual contamination of the cell frac-
tions. Our hepatocyte preparations contain maximally
2% contamination with Kupffer cells.
It is apparent that of the control liposomes almost
30% is taken up in the hepatocyte fraction as com-
pared to less than 10% of the two Gal-PEG-Lip
formulations. These latter values might even be en-
tirely accounted for by the relatively few Kupffer
w xcells contaminating the hepatocyte fraction 28 . It is
Fig. 6. Intrahepatic distribution of Gal-PEG-Lip liposomes. The
livers of the experiments described in Fig. 5 were fractionated
into a parenchymal and a non-parenchymal cell fraction, as
described in Section 2. The amounts of radioactivity in these cell
fractions were converted into the relative uptake values in the
two fractions, expressed as percent of total liver uptake. Values
given are mean"S.D. of three independent experiments. Lipo-
some compositions are as in Fig. 4 and Fig. 5. Open bars,
 .parenchymal cell fraction hepatocytes ; hatched bars, non-
parenchymal cells.
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clear that the rapid hepatic uptake of the Gal-PEG-Lip
liposomes can be accounted for almost entirely by the
non-parenchymal cells. In a few experiments we
further fractionated the non-parenchymal cell frac-
tions into a Kupffer cell and an endothelial cell
fraction and found that only the Kupffer cells con-
tributed to non-parenchymal cell uptake of Gal-
 .PEG -Lip liposomes not shown .10
By including PEG-DSPE in the Gal-PEG-Lip lipo-
somes, we were able to only marginally shift this
distribution in favor of the hepatocytes. Probably, the
PEG-DSPE sterically interferes with the interaction
of the galactose residue with the receptor on the
Kupffer cells, in analogy with the reduced agglutina-
tion activity in Fig. 2.
4. Discussion
 .Phosphatidylethanolamine PE is the most widely
used lipid compound for the construction of lipid-
anchored derivatives for proper incorporation in the
liposomal bilayer. Its popularity is undoubtedly re-
lated to the reactivity of its primary amino group,
which allows versatile derivatization, and to the bio-
logical safety of the compound as such which is a
natural product. From an industrial point of view,
however, PE is less desirable for this purpose because
of high cost. Therefore, we set out to develop an
alternative method for lipophilic derivatization, in-
volving the coupling of the active ingredient drug or
. ligand to a diglyceride residue via a poly ethylene
.glycol spacer. In this paper we specifically describe
the synthesis of diglyceride-anchored galactosyl
derivatives with medium-length PEG chains as spacer
groups. PEG chains of this size have been reported to
possess properties favorable to enhance plasma circu-
lation times of particles to which they are attached,
presumably by diminishing adsorption of opsonic
plasma proteins, which in turn results in diminished
delivery to cells of the mononuclear phagocyte sys-
w xtem 29–34 . In analogy to the design of immunoli-
posomes carrying the antibody at the distal end of a
w xbilayer-anchored PEG chain 35,36 , we speculated
that such a construct would combine the ‘macro-
phage-evading’ properties of the PEG chains with the
specific targeting properties of the galactose residue.
Since the galactose residue is relatively small and
w xthe PEG chains are highly flexible 33 , we antici-
pated that beyond a certain PEG chain length random
coil formation might frustrate the formation of galac-
tose clusters required for optimal interaction with the
w xlectin 37,38 . From agglutination experiments with
the galactose-specific lectin RCA-120 it appeared
that only with the PEG chains the galactose moi-10
eties were properly exposed for adequate interaction
with the lectin. The other two PEG spacers com-
pletely prevented interaction of the liposomes with
the agglutinin.
Monoclonal antibodies as well as some amino
acids have been reported to be recognized even when
they are attached to the distal end of PEG or PEG20 40
w xchains 35,36,39 . Also folate residues attached to
liposomes via a PEG spacer molecular weight70
.3350 were shown to be recognized better by the
folate receptor than folate coupled to liposomes with-
w xout a spacer 40 . Apparently, the effect of a PEG
spacer between the liposome and the ligand on recep-
tor recognition may vary from ligand to ligand. In the
case of galactose recognition, the requirement of
cluster formation may be the determinant parameter
preventing adequate interaction between ligand and
lectin.
The presence of additional PEG chains, anchored40
in the liposomal bilayer in the form of PEG-DMG,
did influence the agglutination behavior. Both rate
and extent of agglutination were substantially de-
creased. This is taken to reflect the steric hindrance
exerted by these relatively long chains, interfering
with the establishment of contact between the sugar
and the binding site on the agglutinin as well as with
the cluster formation required for optimal interaction.
In the animal experiments we used liposomes with an
average diameter of 75–100 nm, sufficiently small to
allow penetration into the space of Disse and thus
w xinteraction with the hepatocytes 27 . We also chose
for a suitably modified liposomal lipid composition
in order to comply with the more rigorous stability
requirements applying to in vivo conditions. We con-
sider it unlikely that the flexibility of the PEG chains
as such, which is held responsible for the screening
effect, would be significantly influenced by the com-
position of the supporting bilayer. Bilayer viscosity,
which clearly is different for the two liposome formu-
lations, may be important, though, since it directly
influences lateral mobility of bilayer constituents.
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This would, however, not be likely to influence the
order in which PEG , PEG and PEG allow10 20 40
recognition of the liposomal galactose by the lectin
molecule and would therefore not affect our choice of
PEG chains for the in vivo experiments.
Liposomes containing 10 or 20 mol% of the Gal-
PEG -Lip were cleared from circulation almost 40-10
fold faster than control liposomes without the galac-
tolipid. The eliminated liposomes were almost exclu-
sively recovered in the hepatic macrophages, the
Kupffer cells, whereas substantial proportions of the
control liposomes were also recovered in spleen and
hepatocytes. This very specific and efficient recogni-
tion by the Kupffer cells is attributed to interaction
with the galactose particle receptor on these cells
w x21 , considering the strongly inhibitory effect of a
N-acetylgalactosamine injection. Apparently, the
galacto-liposomes do not bind opsonizing proteins in
sufficient quantities to successfully compete with the
exposed galactose moiety and to allow significant
interaction with other cells, such as spleen
macrophages. Previously, we reported similar results
with a tri-antennary galactosylated cholesterol deriva-
tive, which also caused liposomes to be rapidly and
w xalmost exclusively taken up by the Kupffer cells 19 .
This makes it unlikely that it is the anti-opsonic
potency of the PEG chain that is responsible for the
lack of uptake by of the Gal-PEG-Lip liposomes by
cells other than Kupffer cells. Rather, it is likely the
overwhelming affinity of the galactose moieties for
w xthe Kupffer cell receptor 21 , irrespective of the
presence of any opsonizing proteins on the liposomal
surface, that causes this highly selective uptake. Peri-
toneal macrophages, which were also reported to
have increased affinity for galactose-exposing lipo-
w xsomes 41 , are not accessible from the blood stream
and therefore will not interfere with our observations.
Additional incorporation of PEG chains in the
bilayers of liposomes containing Gal-PEG-Lip, by
 .means of PEG-DSPE, caused 1 a three-fold increase
 .in blood circulation time, 2 a small but significant
 .decrease in hepatic uptake after 20 h and 3 a small
but significant shift in intrahepatic distribution in
favor of the hepatocytes, comparable to that of the
control liposomes. Probably, the presence of the addi-
tional PEG chains impedes the interaction between
the galactose and its receptor on the Kupffer cells, in
much the same way as it affects the lectin-induced
agglutinability of the liposomes. This would allow a
larger fraction of the injected liposomes to interact
with spleen macrophages, presumably mediated by
macrophage-directed opsonins, and with the hepato-
cytes, either mediated by hepatocyte-directed op-
w xsonins 8,28 or by the asialoglycoprotein receptor on
these cells, which may have different requirements
vis a vis the configuration of the ligand galactose`
groups. We conclude that the anti-opsonic effect of
the PEG-DSPE is predominantly caused by its steric
interference with the interaction between galactose
and its receptor.
The hepatocytic asialoglycoprotein receptor has
 w xbeen studied in great detail see Ref. 42 for a
.comprehensive review . Its affinity for galactose-car-
rying proteins depends on the number and the spatial
arrangement of the terminal galactose moieties:
mono-, di-, tri- and tetra-antennary galactose-
terminated units bind with increasing affinities
w x43,44 . Also the spatial arrangement of the galactose
residues with respect to each other was shown to be
w ximportant in receptor affinity 44 .
The structural requirements of the macrophage
receptor have not been investigated in detail. Van
Berkel and co-workers have shown that ligand size
has a strong influence. Intravenously administered
 .small lipoprotein particles HDL provided with a
surface inserted triantennary galactose were taken up
by the hepatocyte receptor, while larger particles
 .LDL with the same triantennary structure at their
surface were predominantly cleared by the liver
w xmacrophages 45,46 . This was shown to be caused
by specific requirements of the macrophage receptor
rather than of the hepatocyte receptor: the affinity of
macrophage receptor increased sharply with ligand
size, whereas the hepatocyte receptor was virtually
w xinsensitive to ligand size 46 . Confirming an earlier
w xreport by Lee et al. 47 , these authors also demon-
strated, however, a strong influence of spacer arm
w xlength 48 : When the trigalactosyl moiety was sepa-
˚rated from the ligand particle by a distance of 20 A,
both HDL and LDL particles were mainly removed
from circulation by the hepatocytic galactose recep-
tor, while the macrophage receptor was not addressed
w x48 . In our experiments, the use of a long flexible
 .spacer PEG in the galactolipid failed, however, to10
produce measurable in vivo affinity of the Gal-PEG-
Lip liposomes for the asialoglycoprotein receptor;
( )K. Shimada et al.rBiochimica et Biophysica Acta 1326 1997 329–341340
instead, a high affinity for the galactose receptor on
Kupffer cells was observed. The effective length of
˚ the PEG chain is between maximally 35 A fully10
˚.  .stretched and minimally 9 A fully contracted , com-
parable to the spacer length applied by Biessen et al.
w x48 . Rather than the introduction of a long flexible
spacer, the branching and number of closely apposing
galactose residues in the galactolipids are probably
decisive in achieving efficient hepatocyte targeting.
We are currently developing methods to synthesize
PEG lipids carrying triantennary galactose structures.
We conclude that, as was reported for other galac-
tose-exposing liposomal formulations, galactose
residues attached to the liposomal surface via a PEG10
spacer fail to target the liposomes to the asialoglyco-
protein receptor on hepatocytes but rather deliver
them rapidly and highly specifically to the hepatic
macrophage population. This phenomenon might be
profitably exploited, for example, when highly spe-
cific elimination or activation of the liver macrophage
population is required, leaving the macrophages of
the spleen unaffected, by encapsulating inside the
w xliposomes the macrophage-toxic drug clodronate 49
or an immunomodulator such as muramyldipeptide
w x50 , respectively.
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